In addition, a three-gene methylation model (the combination of CDO1, TAC1, and SOX17 for sputum samples; the combination of TAC1, HOXA7, and SOX17 for plasma samples) was reported to discriminate stages I-II NSCLC from control subjects with a sensitivity of 93% and a specificity of 62% in plasma samples and a sensitivity 98% and a specificity of 71% in sputum samples41. The gene discussed is SOX17; the disease is non-small cell lung carcinoma.